19Jun
17Jun
Salem stroke survivor rings stock exchange bell, thanks to new technology
Two partially paralyzed stroke survivors will ring the New York Stock Exchange closing bell Friday night with CEO Paul Gudonis in a symbolic gesture of the company's trade presence on Wall Street. Jessica Peters of Salem and JayJay Johnson of Ohio can ring the closing bell at 4 p.m. on the floor of the NYSE because they wear devices, produced by Myomo, that detect the weak muscle signals in their arms, which activate the devices' motors to move their arms in the desired...
14Jun
Myomo, Inc. Launches MyoPro® 2
Myomo, Inc., a commercial stage medical robotics company, today announced the launch of its next-generation MyoPro® myoelectric arm orthosis (powered brace), the only lightweight wearable device that can restore function in the paralyzed or weakened arms and hands of individuals who have suffered a stroke, spinal cord or nerve injury, or other neuromuscular disability. Read more >>
14Jun
Myomo, Inc. Presents at 2017 Marcum MicroCap Conference
Myomo, Inc., a commercial stage medical robotics company, today announced that its Chairman and CEO, Paul R. Gudonis, will be presenting at the 2017 Marcum MicroCap Conference at the Grand Hyatt Hotel in New York City. Read more >>
13Jun
Myomo closes $5m IPO
Myomo said last week it closed its initial public offering, raising $5 million and listing on the New York Stock Exchange today under the ticker “MYO”. Read more >>
12Jun
Is Reg A+ Crowdfunding Quickly Coming of Age?
Next week on June 12th, Myomo says it will list its shares on the NYSE MKT under the ticker symbol MYO. Myomo raised $7.9 million with $5 million coming from the “crowd” under Reg A+ and $2.9 million from a private sale of restricted securities to accredited investors – most of which were early investors in Myomo. Read more >>
10Jun
Myomo, Inc. Completes Historic Initial Public Offering
Myomo, Inc., a commercial stage medical robotics company, today announced the completion of its initial public offering (IPO) under SEC Regulation A+, raising $5.0 Million through the sale of 665,498 shares of its common stock at a price to the public of $7.50 per share. Read more >>
09Jun
Platelet Biogenesis Raises a $10 Million Series A Financing Led by Qiming U.S. Healthcare Fund
Platelet BioGenesis, a biotech startup developing a process to produce life-saving human platelets from stem cells for therapeutic applications, announced it has successfully raised $10 million in Series A financing. Read more >>
09Jun
Siamab Therapeutics to Present at the 2017 BIO International Convention
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies targeting tumor-associated carbohydrate antigens (TACAs), today announced that Jeff Behrens, president and chief executive officer, will present at the 2017 BIO International Convention. Read more >>
08Jun